Xlife Sciences Partners Twelve Biotech Companies with Grupo Landsteiner, Plans NASDAQ Listing for 2026
核心洞察
Xlife Sciences AG (搜索) announced a strategic partnership involving twelve project companies with pharmaceutical company Grupo Landsteiner (搜索) to accelerate development and partnering opportunities.
The transaction includes technology platform companies, biotechnology firms, medical technology companies, and an AI-focused company, creating a scalable structure combining innovation with industrial expertise.
Both companies are working to establish a US entity with planned NASDAQ listing in 2026, while VERAXA Biotech AG (搜索) prepares for an extraordinary general meeting in January 2026.
Xlife Sciences AG (搜索) has announced the completion of its internal information processes and identified twelve project companies that will be partnered with pharmaceutical company Grupo Landsteiner (搜索). The strategic transaction is designed to establish a company with a scalable structure that combines an innovative portfolio with industrial expertise to accelerate the development and partnering of the projects.
Strategic Partnership Portfolio
The partnership encompasses a diverse range of companies across multiple sectors within the life sciences industry. Technology platform companies Inventum Genetics GmbH (搜索) and inflamed pharma GmbH (搜索) will be included in the transaction, alongside biotechnology and therapy companies alytas therapeutics GmbH (搜索), Baliopharm AG (搜索), Lysatpharma GmbH (搜索) and Firstgene Life Sciences GmbH (搜索).
The medical technology sector is represented by Axenoll Life Sciences AG (搜索), novaxomx GmbH (搜索), saniva diagnostics GmbH (搜索), x-kidney diagnostics GmbH (搜索) and x-nuclear diagnostics GmbH (搜索). Additionally, the artificial intelligence focused company FUSE-AI AG (搜索) will be partnered as part of the comprehensive transaction.
Corporate Structure and NASDAQ Preparations
Xlife Sciences AG (搜索) and Grupo Landsteiner (搜索) are currently collaborating to define the corporate and legal structure of a US company to be established. In parallel, the required accounting, organizational and regulatory frameworks are being implemented to support a planned NASDAQ listing in 2026.
The transaction is not expected to result in any operational changes for the involved project companies. All parties involved welcome the additional expertise, industrial experience and international reach that Grupo Landsteiner (搜索) is expected to contribute to the respective project companies.
VERAXA Biotech Developments
VERAXA Biotech AG (搜索) has successfully resolved all outstanding matters with the commercial register and the auditors. The distribution of invitations for the extraordinary general meeting is planned for January 2026. In the meantime, the VERAXA team is looking forward to a full and engaging schedule surrounding the JP Morgan Health Care Conference in San Francisco.
Leadership Perspective
Oliver R. Baumann, CEO of Xlife Sciences AG (搜索), commented on the significance of these developments: "Both transactions represent major milestones for Xlife Sciences AG. The entire team is working with full commitment to ensure the fastest possible execution. We look ahead to 2026 and would like to thank our shareholders, partners and colleagues for the trust they have placed in us."
The company has outlined its financial calendar for the coming period, with the Annual Report 2025 scheduled for April 28, 2026, the Annual Shareholders Meeting 2026 planned for June 26, 2026, and the Half-Year Report 2026 set for September 24, 2026.